Metagenomi Statistics
Total Valuation
Metagenomi has a market cap or net worth of $66.83 million. The enterprise value is -$75.24 million.
Important Dates
The last earnings date was Tuesday, November 11, 2025, after market close.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Metagenomi has 37.55 million shares outstanding. The number of shares has increased by 51.55% in one year.
| Current Share Class | 37.55M |
| Shares Outstanding | 37.55M |
| Shares Change (YoY) | +51.55% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 11.01% |
| Owned by Institutions (%) | 17.43% |
| Float | 27.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.15 |
| Forward PS | 3.06 |
| PB Ratio | 0.38 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.42, with a Debt / Equity ratio of 0.23.
| Current Ratio | 6.42 |
| Quick Ratio | 6.30 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.87% and return on invested capital (ROIC) is -22.10%.
| Return on Equity (ROE) | -40.87% |
| Return on Assets (ROA) | -19.02% |
| Return on Invested Capital (ROIC) | -22.10% |
| Return on Capital Employed (ROCE) | -42.26% |
| Revenue Per Employee | $153,035 |
| Profits Per Employee | -$439,297 |
| Employee Count | 202 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -4.30% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 1.94 |
| Relative Strength Index (RSI) | 44.21 |
| Average Volume (20 Days) | 463,317 |
Short Selling Information
The latest short interest is 1.23 million, so 3.27% of the outstanding shares have been sold short.
| Short Interest | 1.23M |
| Short Previous Month | 1.40M |
| Short % of Shares Out | 3.27% |
| Short % of Float | 4.54% |
| Short Ratio (days to cover) | 1.65 |
Income Statement
In the last 12 months, Metagenomi had revenue of $30.91 million and -$88.74 million in losses. Loss per share was -$2.38.
| Revenue | 30.91M |
| Gross Profit | -65.18M |
| Operating Income | -92.27M |
| Pretax Income | -90.04M |
| Net Income | -88.74M |
| EBITDA | -86.79M |
| EBIT | -92.27M |
| Loss Per Share | -$2.38 |
Full Income StatementBalance Sheet
The company has $184.11 million in cash and $41.66 million in debt, giving a net cash position of $142.45 million or $3.79 per share.
| Cash & Cash Equivalents | 184.11M |
| Total Debt | 41.66M |
| Net Cash | 142.45M |
| Net Cash Per Share | $3.79 |
| Equity (Book Value) | 178.45M |
| Book Value Per Share | 4.75 |
| Working Capital | 160.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$91.62 million and capital expenditures -$823,000, giving a free cash flow of -$92.45 million.
| Operating Cash Flow | -91.62M |
| Capital Expenditures | -823,000 |
| Free Cash Flow | -92.45M |
| FCF Per Share | -$2.46 |
Full Cash Flow StatementMargins
Gross margin is -210.86%, with operating and profit margins of -298.48% and -287.06%.
| Gross Margin | -210.86% |
| Operating Margin | -298.48% |
| Pretax Margin | -291.26% |
| Profit Margin | -287.06% |
| EBITDA Margin | -280.76% |
| EBIT Margin | -298.48% |
| FCF Margin | n/a |
Dividends & Yields
Metagenomi does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -51.55% |
| Shareholder Yield | -51.55% |
| Earnings Yield | -132.03% |
| FCF Yield | -137.55% |
Analyst Forecast
The average price target for Metagenomi is $9.25, which is 419.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.25 |
| Price Target Difference | 419.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | -12.97% |
| EPS Growth Forecast (5Y) | -8.54% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Metagenomi has an Altman Z-Score of -1.28 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.28 |
| Piotroski F-Score | 1 |
